DR. JAY WANG M.D. NPI 1952509606

NPI Details

DR. Jay Wang, M.D. is a medical oncology internal medicine in Naples, FL with 24 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Jay Wang, M.D. NPI is 1952509606. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Graduation Year:2002

The provider's business location address is:

8350 SIERRA MEADOWS BLVD FL 2
NAPLES, FL
ZIP 34113-328
Phone: (239) 732-3140
Fax: (239) 530-1113

The NPI 1952509606 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Magnesium level (HCPCS:83735)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Protein measurement, serum (HCPCS:84165)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection of drug or substance into vein (HCPCS:96374)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Testosterone (hormone) level, total (HCPCS:84403)
• Red blood count, manual test (HCPCS:85044)
• Folic acid level, serum (HCPCS:82746)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Automated urinalysis test (HCPCS:81003)
• Red blood count, automated test (HCPCS:85045)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Drawing of blood for a medical problem (HCPCS:99195)
• Urinalysis, manual test (HCPCS:81002)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Phosphate level (HCPCS:84100)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Uric acid level, blood (HCPCS:84550)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Hepatitis c antibody measurement (HCPCS:86803)
• Prostate cancer screening; prostate specific antigen test (psa) (HCPCS:G0103)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Blood test, lipids (cholesterol and triglycerides) (HCPCS:80061)
• Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous (HCPCS:G0328)
• Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody (HCPCS:86769)
• Measurement c-reactive protein for detection of infection or inflammation (HCPCS:86140)
• Hemoglobin a1c level (HCPCS:83036)
• Detection test by immunoassay technique for hepatitis b surface antigen (HCPCS:87340)

The enumeration date for this NPI number is 7/4/2007 and was last updated on 9/2/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.